Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Ilya Yuffa, insider at Eli Lilly and

Ilya Yuffa Insider Information

Ilya Yuffa is senior vice president of Eli Lilly and Company and president of Lilly International.

With a tenure of more than 25 years at Lilly, Ilya most recently served as senior vice president of Lilly Bio-Medicines and previously vice president of U.S. Diabetes for Lilly USA from 2018 to 2020. 

Since joining Lilly in 1996 as a financial analyst, Ilya has held a number of positions in finance, business development, sales and general management. He served as managing director of the Israeli affiliate from 2008 until 2011, senior sales director of osteoporosis from 2011 until 2013, and held senior leadership positions within six sigma and ethics and compliance from 2013 until 2017. In 2017, Ilya was named president and general manager of Lilly’s Italy Hub, leading the commercialization of the entire Lilly portfolio in more than 25 countries.

Born in St. Petersburg, Russia, Ilya grew up in Colorado. His career has taken him around the world, and he has lived and worked in the United Kingdom, Czech Republic, Italy and Israel. Ilya earned a bachelor of science degree from Tulane University in 1996, and a master of business administration degree from the London Business School in 2002.

He is a former board member of PhRMA industry association in Israel and Farmindustria in Italy, and he led as vice chair of the Italian American Pharmaceutical Group. Ilya currently serves on the management committee of Business Equity for Indy.

How do I contact Ilya Yuffa?

The corporate mailing address for Mr. Yuffa and other Eli Lilly and executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and can also be reached via phone at (317) 276-2000 and via email at [email protected] Learn More on Ilya Yuffa's contact information.

Has Ilya Yuffa been buying or selling shares of Eli Lilly and?

Ilya Yuffa has not been actively trading shares of Eli Lilly and within the last three months. As an example of a recent trade by , on Sunday, July 3rd, 0 shares of BMO Capital Markets stock. Learn More on Ilya Yuffa's trading history.

Who are Eli Lilly and's active insiders?

Eli Lilly and's insider roster includes Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and's active insiders.

Are insiders buying or selling shares of Eli Lilly and?

In the last year, Eli Lilly and insiders bought shares 1 times. They purchased a total of 202 shares worth more than $49,849.56. In the last year, insiders at the sold shares 37 times. They sold a total of 3,252,406 shares worth more than $915,613,887.78. The most recent insider tranaction occured on June, 27th when Major Shareholder Lilly Endowment Inc sold 41,857 shares worth more than $13,773,045.85. Insiders at Eli Lilly and own 0.1 % of the company. Learn More about insider trades at Eli Lilly and.

Information on this page was last updated on 6/27/2022.

Ilya Yuffa Insider Trading History at Eli Lilly and

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2022Sell1,000$237.45$237,450.00View SEC Filing Icon  
See Full Table

Ilya Yuffa Buying and Selling Activity at Eli Lilly and

This chart shows Ilya Yuffa's buying and selling at Eli Lilly and by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Overview

Eli Lilly and logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $324.71
Low: $317.76
High: $325.40

50 Day Range

MA: $301.37
Low: $282.83
High: $327.27

2 Week Range

Now: $324.71
Low: $220.20
High: $330.85

Volume

1,817,810 shs

Average Volume

3,080,929 shs

Market Capitalization

$308.53 billion

P/E Ratio

48.11

Dividend Yield

1.21%

Beta

0.37
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.